Novo Pakistan Steps Up to Support Insulin Access

Novo Pakistan is stepping up to backing residents living with diabetes against the backdrop of worries regarding access to insulin.

Key points

• Pakistan has an estimated 33 million individuals living with diabetes and more than one million relying on insulin.
• As Pakistan continues to confront the growing burden of diabetes, Novo remains committed to working alongside healthcare professionals, policymakers and patient communities to improve care.
• For individuals who depend on insulin, reliable access to treatment is essential.

What happened

Pakistan has an estimated 33 million individuals living with diabetes and more than one million relying on insulin. Novo Pakistan understands the challenge and strives to address the need for practical, long-term solutions to confront the diabetes burden in the country.

Mehtaz Sultan Khan, General Manager, Novo Pakistan, remarked: "Diabetes care has been at the heart of Novo for more than 100 years and delivering on that commitment remains our priority today. For individuals who depend on insulin, reliable access to treatment is essential. We recognise the reservations being raised and are stepping up to play our part in supporting patients in Pakistan."

As Pakistan continues to confront the growing burden of diabetes, Novo remains committed to working alongside healthcare professionals, policymakers and patient communities to improve care. Individuals concerned concerning their prescribed insulin should speak to a healthcare professional regarding appropriate next steps. They can additionally access educational resources, guidance and connections to healthcare professionals through NovoCare. For information and backing, visit NovoCare.pk or call 021-1111-46686. Stay Connected with ProPakistani. Obtain the latest news and stories wherever you prefer. Follow on Google Discover. Follow on Google News Join WhatsApp. See more ProPakistani stories in Google Search and Top Stories.

The bottom line

For now, novo Pakistan Steps Up to Support Insulin Access remains the part of the story worth watching, and further updates are likely as more details are confirmed.